We are over the moon that our members are telling us that they are excited about having access to HAEGARDA, a subcutaneous C1 esterase inhibitor (C1-INH) prophylaxis therapy for adolescent and adult HAE patients. We want to make sure the message reaches patients everywhere, so to reiterate: YES, HAEGARDA is available to all eligible HAE patients across Canada.
Please read more details on the CSL Behring News Release HERE.
To access HAEGARDA, please contact your HAE specialist or ask a CSL Behring PLUS+ program representative for guidance. If you have questions, please feel free to email email@example.com.